The central role of vascular endothelial growth factor (VEGF) in angiogenesis in health and disease makes it attractive both as a therapeutic target for anti-angiogenic drugs and as a pro-angiogenic cytokine for the treatment of ischaemic heart disease. While VEGF binds to two receptor protein tyrosine kinases, VEGFR1 (Flt-1) and VEGFR2 (KDR), most biological functions of VEGF are mediated via VEGFR2, and the role of VEGFR1 is currently unknown. Neuropilin-1, a non-tyrosine kinase transmembrane molecule, may function as a co-receptor for VEGFR2. Considerable progress has recently been made towards delineating the signal transduction pathways distal to activation of VEGFR2. Activation of the mitogen-activated protein kinase, protein kinase C and Akt pathways are all strongly implicated in mediating diverse cellular biological functions of VEGF, including cell survival, proliferation, the generation of nitric oxide and prostacyclin and angiogenesis. Upregulation of metalloproteinases, activation of focal adhesion kinase and interactions between VEGF receptors and integrins are strongly implicated in VEGF-induced endothelial cell migration. Recent findings suggest important roles for the vasodilators nitric oxide and prostacyclin, in linking post-receptor signaling networks to downstream biological effects and in mediating some in vivo endothelial functions of VEGF.
Introduction
VEGF was initially recognized as a factor which increased vascular permeability, and it is now apparent that Vascular endothelial growth factor (VEGF) is essential this cytokine regulates multiple biological functions in for endothelial cell differentiation (vasculogenesis) and for endothelial cells, among which are enhanced production of the sprouting of new capillaries from pre-existing vessels vasoactive mediators, increased expression of components (angiogenesis) during development [1, 2] . VEGF is also of the thrombolytic and coagulation pathways, suppression thought to play a key role in postnatal angiogenesis during of neointimal vascular smooth smooth muscle cell pregnancy, wound healing and in human pathophysiologi-(VSMC) hyperplasia, inhibition of thrombosis, hypotencal conditions including cancer, rheumatoid arthritis, ocusion and vasorelaxation [5, 6] . VEGF is also a pleiotropic lar neovascular disorders, and cardiovascular disease [3- factor with effects on diverse cell types and tissues [7] [8] [9] [10] [11] . 5].
The complexity of VEGF biology is paralleled by the emerging complexity of interactions between VEGF ligands and their receptors, and the downstream signaling pathways they mediate. This review considers the signal 2. VEGF ligands location showed only blood vessel hyperplasia [32] . VEGF-B knockout mice are healthy and fertile but have VEGF (VEGF-A) is a member of a family of closelysmaller hearts and exhibited vascular dysfunction after related growth factors, which now includes VEGFs B, C, coronary occlusion and impaired recovery following ex-D, E and placenta growth factor (PlGF) [1, 12, 13] . All of perimental cardiac ischaemia [34, 35] . VEGF-B has been these polypeptides are endogenously expressed in mamreported to induce expression and activity of urokinase mals except VEGF-E which is encoded by the double type plasminogen activator [36] . A role for PlGF in stranded DNA virus, orf. Alternative splicing of human placental angiogenesis has been proposed [37] , but PlGF VEGF mRNA from a single gene containing eight exons homodimers appear to have little effect on angiogenesis in gives rise to at least five different isoforms of 121, 145, vivo. However, VEGF / PlGF heterodimers do bind to 165, 189 and 206 amino acid residues [14, 15] . Exon degrees via a region rich in charged basic amino acid VEGF, VEGF receptor(R)1 (known as Flt-1) and VEGFR2 residues encoded by exon 6 and an exon 7-encoded (KDR / Flk-1) which share |44% amino acid homology domain [14] . Human VEGF is glycosylated at Asn75 [12, 13] . VEGF-C and -D bind to a third receptor, VEGFR3
165 [14] and is typically expressed as a 46-kDa homodimer of (Flt-4), which does not recognize VEGF-A. VEGF-C and 23-kDa monomers and is the most abundant and, in in -D also bind VEGFR2 with lower affinity than they bind vitro studies, most biologically active form [13, 14] .
VEGFR3 [39, 40] . PlGF and VEGF-B bind with high-VEGF and VEGF are also biologically active in affinity only to VEGFR1 [36, 41] , while VEGF-E binds 121 145 endothelial cells. specifically to VEGFR2 [42] . The specificities of members The central role of VEGF in embryonic blood vessel of the VEGF family for their receptors are illustrated in development has been highlighted by the finding that Fig. 1 . targeted inactivation of only a single allele of the VEGF The three VEGF receptor tyrosine kinases are structuralgene in mice causes a lethal impairment of angiogenesis ly related to the PDGF family of receptors (class III) and [17] . Transgenic homozygous mice expressing only have a similar domain structure characterized by cyto-VEGF and lacking the longer heparin-binding VEGF plasmic regions with an insert sequence within the cata- 120 164 and VEGF isoforms coded by exons 6 and 7 [18] die lytic domain, a single hydrophobic transmembrane domain 189 shortly after birth due to bleeding and ischaemic carand seven immunoglobulin-like domains in the extracelludiomyopathy. lar regions (Fig. 1) . The reported affinities of VEGF for VEGF expression is regulated by hypoxia, which in-VEGFR1 and VEGFR2 are, respectively, 16-114 pM and duces binding of the transcription factor complex, hypoxia 0.4-1 nM [12,13, [43] [44] [45] [46] . VEGFR3 is synthesized as a inducible factor 1, to the hypoxia response element in the glycosylated 195-kDa molecule which undergoes cleavage VEGF gene promoter region [19] [20] [21] [22] . VEGF mRNA in its extracellular domain to generate 120-and 75-kDa expression is also regulated in VSMC, keratinocytes and chains which are linked by disulphide bridges [12] . other cultured cell types by diverse stimuli including basic Elucidation of the crystal structure and mutational fibroblast growth factor (bFGF), TGF-b and interleukin-1b analysis of VEGF has identified residues critical for 9 -108 [23] [24] [25] [26] [27] [28] . binding to VEGFR1 and R2 [47, 48] . Analysis of deletion VEGF-B and PlGF are both expressed as two isoforms and point mutants and chimeric forms of VEGFR1 and R2 produced from alternative splicing [29, 30] . VEGF-C and indicate that Ig-like extracellular domains 2 and 3 are the -D are produced as large precursor forms which submost important for ligand binding [48] [49] [50] . Monomeric sequently undergo processing to variety of partially proreceptors have 100-fold less affinity for VEGF, which cessed and mature forms with different receptor-binding preferentially binds predimerized receptors [49] . Heterospecificities [31] . The role of these VEGFs is not well dimeric receptors with one functional and one non-funcunderstood at present. A major function of VEGF-C may tional unit are unable to transduce signals and antagonize be as a growth factor for lymphatic vessels [32, 33] .
VEGF activity. Transgenic mice overexpressing VEGF-C in keratinocytes Targeted disruption of VEGFR1 and R2 in mice preof the skin epidermis develop enlarged lymphatic vessels vents normal vascularization and embryonic development, in their skin but mice overexpressing VEGF in the same but the two knockouts have distinctive phenotypes [51, 52] . [54] [55] [56] (Fig. 1) . NP-1 is a non-tyrosine kinase trans-(HUVECs), while higher concentrations reduced binding membrane protein originally identified as a receptor for [61] . The glycosylphosphatidylinositol anchored HSPG, members of the semaphorin / collapsin family of secreted glypican-1, has also been reported to restore VEGF binding polypeptides implicated in axonal guidance and neuronal to heparinase-treated cells [62] . patterning [57] . Overexpression of NP-1 in mice causes diverse abnormalities in the embryonic cardiovascular system, including excess capillaries and blood vessels, 4. VEGF receptor signaling dilated blood vessels, and malformation of the heart [58] . NP-1 knock-out mice displayed impaired neural vasculari-4.1. VEGFR1 zation, defects in development of the aorta and other large blood vessels, and aberrant yolk sac vascularization [59] .
It remains enigmatic whether VEGFR1 is able to transIn the human fetal heart, NP-1 is expressed in the mit a biologically meaningful signal in endothelial cells. endocardium, coronary vessels, myocardial capillaries and Studies of VEGFR1 signaling have yielded contrasting epicardial blood vessels and is co-expressed with VEGFR1
results. Whereas tyrosine 1169 in the VEGFR1 kinase domain has been reported to provide a binding site for main. A total of four major autophosphorylation sites have PLC-g [63] and VEGF caused activation of phospholipase been identified in VEGFR2, Y951, Y996, Y1054 and C-g but weak activation of extracellular signal-regulated Y1059 [75] . Y951 and 996 are in the kinase insert region, kinase (ERK) in VEGFR1-expressing NIH3T3 cells [64] , and Y1054 and 1059 are in the kinase domain. Like other VEGFR1-expressing porcine aortic endothelial (PAE) cells receptor protein kinases, VEGFR2 has been shown to showed ERK activation but no effect on PLC-g activity in associate with a number of src homology (SH) 2 domain response to PlGF [65] . VEGFR1 was found to support proteins, including the adapter proteins Grb2, Nck and Shc
21
Ca fluxes in Xenopus laevis oocytes [44] and VEGFR1 and the SH2 domain protein tyrosine phosphatases SHP-1 21 and SHP-2 [76, 77] . VEGFR2 has also been reported to has been reported to mediate Ca mobilization in associate with and be regulated by the protein tyrosine trophoblast cells [66] , but PlGF and VEGFR1 did not 21 phosphatase, HCPTPA [78] . mediate Ca mobilization in HUVECs [67] . VEGFR1 was Overall, most functional endothelial VEGF cell sigalso reported to interact with the p85 subunit of phosphanaling described to date is mediated via VEGFR2 or tidylinositol 39-kinase (PI3K) in a yeast two-hybrid system strongly suspected to involve VEGFR2 on the basis of [68] , but so far this has not been associated with a ligand specificity. Thus, VEGF, but not the VEGFR1-biological activity in VEGFR1-expressing cells.
specific ligand, PlGF, induced NO and prostacyclin (PGI ) The VEGFR1-specific ligand, PlGF does not stimulate 2 production in HUVECs [79, 80] . VEGF stimulates NO either migration or proliferation in HUVECs, and VEGF production [80] , increased endothelial constitutive nitric has no reported biological effects in PAE / VEGFR1 cells. 21 oxide synthase (eNOS) expression [81] , Ca mobilization A recent study suggests that PlGF, but not VEGF, can [68] , proliferation and migration [46] in porcine aortic stimulate ERK activation and mitogenesis, but not migraendothelial cells (PAE) expressing VEGFR2, but not in tion in PAE / VEGFR1 cells [65] . The best-characterized PAE / VEGFR1 cells. VEGF also stimulated PLC-g and biological responses mediated by VEGFR1 are the stimula-ERK activity in VEGFR2-expressing NIH3T3 cells [82] tion of migration and increased tissue factor expression in and VEGFR2 is strongly implicated in activation of the monocytes [8, 43] , though their biological role in vivo is PI3K /Akt pathway [83] and of the tyrosine kinase c-Src unclear. VEGFR1 is also implicated in VEGF stimulation [84] . Almost all of the ensuing discussion of biologicallyof metalloproteinase expression in SMC [69] . Remarkably, relevant VEGF signaling relates to VEGFR2-mediated mice expressing only the extracellular domain of VEGFR1 signaling. and lacking its cytoplasmic kinase domain are fertile and develop normally [70] . Suppression of VEGF-induced 4.3. VEGFR3 migration of macrophages in vitro was the only observed phenotype in these mice [70] .
VEGF-C treatment of PAE expressing either VEGFR 3 There is increasing evidence that VEGFR1 functions as or VEGFR2 caused actin reorganization and cell migration a negative regulator of VEGFR2. A soluble form of the [85] . Evidence that VEGFR2 is essential for mediating extracellular VEGFR1 domain occurs naturally and oversome biological functions of VEGF-C comes from a study expression of this form, but not of an artificial soluble in which a mutant VEGF-C that can still bind and activate VEGFR2, inhibits VEGF-induced migration and prolifer-VEGFR3 but cannot ligate VEGFR2 or activate ERK, was ation of human microvascular endothelial cells and unable to induce vascular permeability and proliferation of HUVECs by forming an inactive complex with VEGF and bovine capillary endothelial cells [86] . the full-length VEGFR2 [71, 72] . A study of chimeras made between the extracellular domain of the receptor for colony-stimulating factor 1 and the kinase domains of 5. Biological functions of endothelial VEGF receptor either VEGFR1 or R2., found that activation of the R1 signaling kinase domain chimera with CSF-1 suppressed ERK activation and proliferation mediated via the R2 kinase 5.1. Endothelial cell survival chimera [73] . Analysis of domain swapping between VEGFR1 and VEGFR2 indicates that a short motif A fundamental cellular mechanism by which VEGF (ANGG) unique to the intracellular juxtamembrane promotes the formation of new blood vessels and main-VEGFR1 domain can suppress VEGFR2-mediated sigtains their integrity is the activation of endothelial cell naling and cell migration [74] .
survival or anti-apoptotic signaling (Fig. 2) . VEGF was first shown to be a survival factor for retinal endothelial 4.2. VEGFR2 cells [87] . VEGF inhibits HUVEC apoptosis in part by activating the anti-apoptotic kinase, Akt / PKB, via a PI3K-VEGFR2 is activated through ligand-stimulated receptor dependent pathway [83, 88] (Fig. 2) . Long-term effects of dimerization and transphosphorylation (autophosphoryla-VEGF on endothelial cell survival are probably mediated tion) of tyrosine residues in the cytoplasmic kinase dothrough upregulation of components of the anti-apoptotic survivin and X-chromosome-linked IAP (XIAP) which VEGF-dependent angiogenesis [101] . inhibit terminal effector small pro-domain caspases [90] .
Other signaling pathways may also play a role in The non-receptor protein tyrosine kinase, focal adhesion endothelial cell survival functions of VEGF. For example, kinase (FAK), plays a key role in integrin-dependent the protein kinase C (PKC) activator phorbol myristate signaling [91] and is strongly implicated in the mainteacetate, was shown to promote survival of HUVECs and nance of survival signals in several adherent cell types endothelial cell tube formation in 3-D collagen gels [102] . including endothelial cells [92, 93] . Consistent with a role for FAK in VEGF survival signaling, VEGF increases 5.2. Proliferation tyrosine phosphorylation and focal adhesion association of FAK and the FAK-associated protein paxillin in HUVECs VEGF stimulates VEGFR2-mediated DNA synthesis and [94] [95] [96] (Fig. 2) , and stimulates tyrosine phosphorylation proliferation in a variety of endothelial cell types (Table of the FAK-related tyrosine kinase, Pyk2, in a bone 1). VEGF strongly induces the activity of extracellular marrow endothelial cell line [97] .
signal-regulated kinases (ERKs) 1 and 2 and activation of Integrin a b is an important survival system for this pathway presumably plays a central role in the v 3 nascent blood vessels during angiogenesis [98] . Cross-talk stimulation of endothelial cell proliferation [79, 94] (Table  between this system and VEGF receptors is indicated by 1, Fig. 3 ). VEGF also induced the MAP kinase pathway the findings that VEGFR2 has been reported to associate leading to activation of c-Jun N-terminal protein kinase selectively with a b and VEGF mitogenicity and receptor (JNK). VEGF-induced mitogenesis, cyclin D1 synthesis work is an attractive mechanism for integrating cell selective inhibitor of ERK activation [103] . Interestingly, survival and angiogenic functions of VEGF, a caveat to expression of the dominant negative Y185F ERK2 mutant this is that b -null mice exhibited no defects in retinal also blocked JNK activation by VEGF indicating that the [84] BAEC Association of src with KDR, PLC-g activation, intracellular Ca NO production, PGI production 2 mobilization [128] Bovine microvascular EC NO and PGI production Permeability 2 [161] Bovine retinal EC ERK and PKC-mediated upregulation of Ang2 Gene expression [148] Bovine retinal EC KDR, caveolin 1 and eNOS translocation to the nucleus Intracellular trafficking BAEC [156] Bovine pulmonary artery EC Loss of b-catenin staining from adherens junctions. PLC-g, Cell proliferation, permeability paxillin and b-catenin phosphorylation [81] Bovine adrenal cortex EC PKC-mediated eNOS upregulation Gene expression [146] Porcine brain microvascular EC cGMP production Permeability [151] Porcine isolated coronary venules PLC-g phosphorylation, PKC-mediated eNOS phosphorylation Permeability [77] PAE/VEGFR Shc-Grb2 complex formation, DNA synthesis Grb2 and Nck association with KDR, VEGFR2 specific signaling and SHP1 and SHP2 association with KDR proliferation [76] BAEC PLC-g, Ras GTPase-activation, Nck tyrosine phosphorylation [123] HUVECs PLD activation Migration 21 [67] HUVECs Ca mobilization VEGFR2 specific signaling [80] HUVECs, PAE/VEGFR NO, cGMP production VEGFR2 specific signaling a BAEC, bovine aortic endothelial cells; PI3K, phosphatidylinositol 39-kinase; PKG, protein kinase G. Other abbreviations are defined in the text.
and activation leading to generation of diacylglycerol and 107] (Fig. 3) . Intriguingly, VEGF-induced proliferation inositol 1,4,5-trisphosphate and subsequent activation of was reported to be dependent on a NO-mediated reduction 21 PKC and Ca mobilization. Studies using PKC inhibitors in PKCd activity [108] . Consistent with this finding, and isoform-specific anti-sense approaches indicate that overexpression of PKCd retards cell-cycle progression of activation of PKC and particularly PKCa and z isoforms, microvascular endothelial cells [109] . These findings sugplays a crucial role in VEGF mitogenic signaling [104- gest that the mitogenic effects of VEGF may be mediated at Pennsylvania State University on February 22, 2013 http://cardiovascres.oxfordjournals.org/ Downloaded from phorylation and receptor association of the adapter protein, GRB-2, subsequent stimulation of the guanine nucleotide exchange protein SOS and activation of ras which in turn activates Raf-1 and the distal ERK cascade [110] . Though the role of this pathway in VEGF-stimulated activation of Ras or ERKs has not been demonstrated, it was reported that VEGF induces ras-independent and PKC-mediated induction of the Raf-MEK-ERK pathway [107, 111, 112] , findings which suggest that VEGFR2 may be unique among receptor tyrosine kinases in activating the ERK cascade via a Ras-independent pathway mediated via PKC. Two reports have suggested another novel pathway for VEGF-induced ERK activation involving NO-mediated Raf-1 activation, but the mechanism involved is unclear [113, 114] .
Migration
Degradation of the basement membrane is essential for endothelial cell migration and is a key early step in the VEGF induces tyrosine phosphorylation of FAK and via a coordinated increase in activity of some PKC paxillin and promotes recruitment of FAK to new focal isoforms and decrease in PKCd activity. adhesions in HUVECs [94] (Fig. 4) . It was reported that The major pathway through which protein tyrosine the heat shock protein, Hsp90, facilitated FAK phosphorylkinase receptors activate ERKs involves tyrosine phosation and inhibition of Hsp90 with geldanamycin arrested Fig. 4 . VEGF chemotactic signaling. VEGF has been shown to activate FAK via an unknown mechanism. FAK activity may also be induced via engagement of integrin a b . VEGF-induced activation of the p38 kinase has also been implicated in reorganization of the actin cytoskeleton. Recent VEGF-induced migration [95] . Via an independent pathproduction of NO and prostacyclin (PGI ) [79, [124] [125] [126] [127] [128] , 2 way, VEGF activated p38 MAP kinase in HUVECs and the and these intercellular mediators have been implicated in p38 kinase inhibitor SB203580 inhibited actin reorganizamediating diverse biological effects of VEGF including tion and cell migration whereas the MEK inhibitor angiogenesis, increased vasopermeability and inhibition of PD98059 had no effect on these biological effects neointimal VSMC hyperplasia [5] . In common with other [95, 117] .
activators of eNOS, short-term NO production induced by There is growing evidence that NO production may play VEGF probably involves activation of the constitutive 21 a role in VEGF-induced endothelial cell migration (Fig. 4) . eNOS isoform in part through VEGF-induced Ca mobili-VEGF induces NO production and NO is implicated in zation (Fig. 5) . Another mechanism for VEGF-dependent non-chemotactic scalar movement (podokinesis) of endo-NOS activation may be through activation of the heat thelial cells and as a permissive factor in VEGF-induced shock protein Hsp 90 or an Hsp 90-associated protein endothelial cell migration [118, 119] and angiogenesis [129] . Activation of c-Src was reported to mediate VEGF- [120, 121] . NO has been reported to regulate focal adhesion stimulated NO and PGI production through PLC-g activa- . In this study it was unclear, pathways in migration signaling (Fig. 3) . Direct evidence however, how c-Src couples with and activates PLC-g. for a role of NO has come from a recent study in which VEGF-induced PGI production results from PKC-me-2 Akt-dependent phosphorylation of eNOS at serine 1177 diated ERK1 / 2 activation and ERK-mediated phosphoryla- 21 was shown to be required for VEGF-induced cell migration tion and activation of cPLA [79] (Fig. 5) . The Ca -2 [122] . chelating agent BAPTA-AM also prevents production of PLC-g activation is implicated in mediating cellular PGI [112] . These findings suggest that stimulation of 2 responses linked to VEGF-induced cell migration [65, 116] PGI biosynthesis by VEGF occurs via ERK-dependent 2 and VEGF-induced phospholipase D activation via a cPLA activation, while release of PGI is mediated via a 2 2 21 pathway sensitive to the PKC inhibitor Ro 31-8220, has Ca -triggered pathway (Fig. 5) . VEGF-induced PGI 2 been more tentatively implicated in the cell migratory production and ERK activation in HUVECs were unaffectresponse to VEGF [123] .
ed by inhibitors of eNOS, suggesting that VEGF signaling leading to NO and PGI generation bifurcates upstream of . c-Src has been implicated in signaling upstream of PLC-g. Akt activation leads to 3 21 phosphorylation and activation of eNOS (eNOS-P), providing a mechanism for sustained Ca -independent NO synthesis. PKC activation is strongly implicated in VEGF-induced ERK activation. ERK activation mediates cPLA activation, mobilization of arachidonic acid (AA) and PGI synthesis. Increased cytosolic Ca stimulates the cellular release of PGI . PKC is also reported to mediate VEGF-induced upregulation of eNOS, another mechanism 2 leading to long-term NO generation.
at Pennsylvania State University on February 22, 2013 http://cardiovascres.oxfordjournals.org/ Downloaded from sion occurs via activation of VEGFR2 and was inhibited vascular protective effects via NO and PGI production are 2 by selective PKC inhibitors suggestive of a role for PKC in both consonant with the view that VEGF may be useful for VEGF-dependent gene expression [81] . VEGF-induced Akt promoting therapeutic angiogenesis in the ischaemic heart activation mediates phosphorylation of eNOS at serine [4] , and for reducing neo-intima formation in situations 21 1179 to cause Ca -independent NO generation [132, 133] . such as coronary and peripheral bypass graft stenosis [5] . Combined with VEGF-induced upregulation of eNOS This favourable assessment of the beneficial effects of mRNA, this could be an important signaling mechanism VEGF for cardiovascular disease should, however, be underlying the stimulation of long-term NO production by tempered in the light of recent findings. Increasing evi-VEGF, and may contribute to other biological functions of dence suggests that VEGF is insufficient for viable colAkt signaling (Figs. 4 and 5) .
lateralization of the ischaemic heart, a process which NO and PGI are best known as vasodilators, but they involves arteriogenesis and VSMC proliferation rather than 2 have several vascular protective effects, including inhibiangiogenesis. Moreover, intra-plaque neovascularization tion of VSMC proliferation, anti-platelet actions, and in the has long been recognized as a feature of atherosclerosis case of NO, inhibition of leukocyte adhesion [5] . VEGF and recent findings suggest that antiangiogenic agents can may have similar vascular protective effects through reduce atherosclerosis in the apo E-deficient mouse. These enhanced NO and PGI production [5] . VEGF protein or findings suggest that while VEGF may not be an effective 2 gene transfer accelerates reendothelialization and reduces agent for stimulating myocardial collateral artery formaintimal thickening and thrombus formation following tion, VEGF-driven neovascularization could contribute to balloon endothelial denudation in the rat carotid artery atherogenesis. These issues are discussed in more detail in [5, 134, 135] . Evidence that VEGF has NO-dependent vasour recent review [5] . cular protective effects independent of angiogenesis or endothelial cell proliferation, comes from the finding that 5.5. VEGF signaling in the regulation of vascular periadventitial VEGF gene transfer in the rabbit carotid permeability artery suppressed VSMC neo-intimal hyperplasia induced by a perivascular silastic collar without endothelial injury VEGF was originally identified as a factor which [125] . The endothelial nitric oxide synthase (eNOS) inhibincreased vascular permeability [7, 141] . The signaling itor L-NAME prevented VEGF-mediated inhibition of neomechanisms which underly this effect remain largely intima formation in this model [125] . The paradoxical obscure, however. ability of VEGF to inhibit VSMC proliferation while
The formation of fenestrae, specialized regions of the stimulating endothelial cell mitogenesis may reflect difplasma membrane that are highly permeable to small ferential effects of NO and PGI on growth of these two solutes, may be an important mechanism by which VEGF 2 cell types, reflecting either differential expression of PGI modulates vascular permeability. Fenestrated endothelia 2 receptors or a divergence in growth regulatory mechanisms are restricted to the kidney glomeruli, gastrointestinal tract, in the two cell types.
endocrine organs and particular areas of the brain, and are An anti-thrombotic effect of VEGF may result both absent from most of the brain, skeletal muscle, skin and from inhibition of platelet aggregation mediated by NO lung [142, 143] . A correlation between tissues maintaining and PGI (Fig. 2) , and from VEGF-induced expression and high levels of VEGF expression in the adult and the 2 activation of the serine proteases, urokinase and tissue type presence of fenestrated endothelia has been noted [143] . plasminogen activator [136] , which cleave plasminogen to
The neovasculature induced by VEGF in glioblastoma is generate the key thrombolytic enzyme plasmin. Paradoxialso highly fenestrated, in contrast to the non-fenestrated cally, VEGF also has potentially pro-thrombogenic effects, endothelia of the blood-brain barrier [144, 145] . In cultures including the induction of endothelial von Willebrand of bovine adrenal cortex endothelial cells and porcine brain factor (vWF) secretion [79, 137] , essential for platelet microvessel endothelial cells, VEGF induced the formation adhesion to subendothelial collagen, and upregulation of of abundant fenestrae [143, 146] . The signaling pathways tissue factor [54] , an essential step in the extrinsic pathway mediating VEGF-induced fenestration are unclear, though of coagulation and clot formation. However, VEGF only a permissive environment involving changes in the comappears to increase surface expression of active tissue position of the extracellular matrix may be required factor on endothelial cells in cooperation with tumor [143, 147] . VEGF-induced formation of fenestrations is necrosis factor-a [138] . Furthermore, other findings point associated with caveolae, small invaginations of the plastowards roles for von Willebrand factor and tissue factor in ma membrane implicated in endocytotic and transcytotic angiogenic functions of VEGF. Mice embryos deficient in transport [143, 148] . VEGF also induces the appearance of tissue factor have an impaired pattern of extraembryonic vesicular-vacuolar organelles [149, 150] which interconnect angiogenesis [139] , and von Willebrand factor increases upon stimulation to form channels that connect the blood endothelial cell adhesion, suggestive of a role in the vessel lumen to the interstitium and facilitate passage of maintenance of endothelial integrity [140] .
molecules. The stimulation of angiogenesis and the enhancement of A role for NO and PGI in mediating VEGF-induced vascular permeability is supported by the observations that differentiation, and the complex cellular changes involved the cyclooxygenase inhibitor indomethacin and the eNOS in branching angiogenesis. These responses presumably inhibitor L-NAME both inhibited permeability changes involve the generation of long-range signals mediated induced by VEGF in vivo as measured by the Miles assay through a programme of gene expression. VEGF has been [128] . Several studies also implicate PLC-g tyrosine shown to induce the expression of several transcription 21 phosphorylation, mobilization of intracellular Ca and factors (Table 1 ) [21] , but if or how these are linked to PKC activation as effectors of VEGF-induced venular developmental or angiogenic effects of VEGF remains to permeability [151] .
be fully elucidated. Phosphorylation of components of intercellular endo-
The potential for using VEGF and anti-VEGF therapy thelial adherens and tight junctions may mediate disruption for human disease is an exciting one. In order to effectiveof cell-cell adhesions, leading to increased vasoperly harness this potential, an improved understanding of the meability [152] . VEGF increased phosphorylation of the signal transduction mechanisms which mediate the comadherens junction components VE-cadherin [153] , and bplex biological functions of VEGF will be essential, and catenin [154] , though these effects were not associated in may itself generate new approaches for treating human HUVECs with readily detectable changes in the morpholodisease. gy or organization of adherens junctions. VEGF also stimulated tyrosine phosphorylation of the tight junction proteins, occludin and zona occluden 1 [155] . be to elucidate the endothelial function of neuropilin-1. goal will be to delineate the pathways through which order to generate information required for endothelial cell 
Perspectives and concluding remarks

